MCI diagnostic marker, MCI diagnostic kit and corresponding detection method

Abstract

The invention relates to a diagnostic marker for prophase mild cognitive function impairment (MCI) of Alzheimer's disease. The marker is a plasma long-chain non-coding ribonucleic acid (lncRNA), and the plasma lncRNA comprises one or more of ENST00000549762, NR_024049, T324988 or ENST00000567919. The invention further relates to application of the marker and a corresponding kit. The MCI diagnostic marker has the beneficial effects that the peripheral blood lncRNA biomarker with higher diagnostic value on MCI is found for the first time, an effective marker is provided for low-damage diagnosis of MCI by adopting peripheral plasma, and early diagnosis and early intervention of Alzheimer's disease are facilitated.

Description

[0001] This application is a divisional application of an invention patent application with an application date of July 31, 2020, an application number of 202010760263.8, and an invention title of "MCI diagnostic marker, MCI diagnostic kit and corresponding detection method". technical field [0002] The invention relates to the technical field of prodromal stage of Alzheimer's disease, in particular to the technical field of diagnostic markers, specifically a mild cognitive impairment diagnostic marker and its application. Background technique [0003] Alzheimer's disease (AD) is a chronic neurodegenerative disease, which has become the most common type of senile dementia. Neuropsychiatric symptoms and behavioral abnormalities, the main pathological features are senile plaques formed by the deposition of amyloid protein outside the nerve cells and neurofibrillary tangles caused by the hyperphosphorylation of microtubule-associated Tau protein in the nerve cells. apoptosis. ...

AI Technical Summary

Problems solved by technology

At present, the diagnosis methods of AD and MCI are mainly through the consultation of professional doctors, according to the medical history and scale scores, mainly through the Montreal Cognitive Assessment Scale, a complete set of neuropsychological tests, the Mini-Mental State Scale and the Clinical Dementia Scale, etc. , but the evaluation of the scale is time-consuming and labor-intensive, and relatively inaccurate

Auxiliary examinations mainly include brain structural imaging examinations, which can observe the macroscopic changes of the patient's brain structure, but cannot detect early, especially the characteristic changes of MCI

Senile plaque imaging detection is currently the gold standard for AD diagnosis, and pathological changes can be seen, but it is expensive and has no clinical application in China

Therefore, there is no early diagnosis method of clinical biomarkers that can be promoted and applied clinically in China. Exploring the use of peripheral blood biomarkers to screen potential MCI patients will help the early diagnosis and treatment of AD.

Images